Predicting Corticosteroid Free Endoscopic Remission with Vedolizumab in Ulcerative Colitis

This work uses random forest modeling on a cohort of 594 patients with Vedolizumab to predict the outcome of corticosteroid-free biologic remission at week 52 on the testing cohort. Models were constructed using baseline data or data through week 6 of VDZ therapy.